- For people with late-stage non-small cell lung cancer (NSCLC) undergoing initial immunotherapy treatment, a key question has been how long they should continue the therapy for the best chance at survival.
- A recent retrospective study examined medical records to compare the outcomes of people who stopped immunotherapy around the two-year…
Read the full article here
